Actelion is pleased to announce the very first positive outcome of a clinical trial study on the new ITSTICAN compound. The main indication for this new molecule is to cure the U.A.S.S. (User Allergy Severe Syndrome). The site and patient recruitment has been successfully conducted in the GITS department in Allschwil. Current research and surveys indicate that more than 25% of clinical trial sites are unproductive but this could not be the case here. Obviously the new drug is potent: the main side effect is a significant reduction of the head's size. It is particularly potent on the patients located in a place known as "the Golf Corridor". The Safety physicians are currently working with the help of the data mined by the sponsors and CROs to determine whether this symptom should be considered as an adverse event. To help the company on these promising ongoing operations, please consider the following warning. If any of your colleagues from GITS comes to see you showing one of the following behavior: . Asking you about your needs. . Caring about the quality of the IT service delivered. . Planning with you the transition of an infrastructure on which relies your applications by analyzing the impact on the service delivered. . Trying to understand your daily business concerns or your core business issues and tries to help you building the future. . Trying to solve a recurring issue by using his expertise to find its related root cause. . Showing some Open Communication Signs _or_ wanting to base his attitude on trust _or_ wanting to promote teamwork / Innovation / measured results. . or being simply understandable, Don't be afraid. DO NOT CALL THE POLICE! DO NOT RUN! Be indulgent: this person is probably on drugs with the actual compound, not the placebo. Stay calm. Grab the dozens of cases pending for at least the last 5 years. Take a deep breath. And start working for real.
